A For-Profit Global Collaboration for Medicines Discovery
Improving the quality of life and saving lives.
Generating outsized returns for our investors.
Improving the quality of life and saving lives.
Generating outsized returns for our investors.
“Large pharma companies do little new drug innovation” StatNews.com
LSI was created with the knowledge that academia is a primary resource from whom big pharma seeks embryonic creations of novel medicines.
By providing academia with long term capital, enhanced development and technology transfer, and an alignment of interests; LSI accelerates the creation of bench to bedside novel medicines, improves the quality of life of humankind and provides outsized rates of returns for LSI Investors.
Life Sciences Institute (“LSI”) is a disruptive, global accelerator of life-saving medicines providing outsized returns to its investors.
LSI’s Research Partners are scientific academic universities that have the highest concentration of Nobel laureates who customarily collaborate across borders and institutional lines to further scientific research and now have the additional incentive of financial alignment, substantial capital and commercialization technologies.
This aggregation of the giants of medical science with long-term capital creates a facultative company, which will be transformative to science and provide outsized rates of returns to its investors.
LSI is the fulfillment of a long-standing vision, developed over a substantial period of time.
The company’s global scale and substantial financial resources enable LSI to bring medicines development to the apex of commercialization.
The world’s leading scientists
Developing new medicines and harnessing existing discoveries
Substantial databases of genetic material
Commercialization through partnerships, licences, JVs, divestment
Market analysis
Clinical trial applications
Regulatory submissions
IP portfolio strategy
“Hub of the Wheel”
Capital investment, Oversight, Funding
Strategic initiatives
Financial reporting
SINGULAR FOCUS
The creation of life-saving and life-enhancing medicines.
RESEARCH ENGINE
Enables the giants of medicine at the world’s top scientific academic universities to create life-saving drugs with reliability of capital and without big pharma bureaucracy.
MINIMIZED COMMERCIAL SPEND
As LSI is not involved in manufacturing, marketing, distribution, sales or lobbying, LSI’s SG&A is significantly lower than those of big pharma.
UNPRECEDENTED GENOMIC ACCESS
Access to vast databases of genetic material, initially on over 9M patients, provides the ability to discover rare genetic variances, for the sole purpose of new medicines discovery.
GLOBAL COLLABORATION
LSI’s unique structure enables the giants of medicine to collaborate with their peers at other global leading medical scientific institutions.
MITIGATION OF RISKS
LSI, having eight separate asset classes of research focus and the uncorrelated development of these assets, provides diversification of nonsystematic risk.
FAIL FAST SUCCEED FASTER
LSI’s computational research and machine learning (AI) are an analytic and strategic advantage which enable LSI to achieve groundbreaking speed of innovation.
PROFOUND SYNERGIES
LSI’s highly advanced engagements with leading scientists in rare disease and vision sciences make evident the synergies that arise from collaboration and shared resources. These synergies extend to the specific molecular development of numerous disease asset classes.
LSI FELLOWS AND SCHOLARS
LSI Research Fellows will be elected by the Research Partners at a time of deserve and be awarded a financial remuneration. LSI Scholars will be elected by the Research Partners. LSI Scholars will receive full academic scholarships and free room and board, travel, a stipend, and all and any academic tutelage or matriculation at no cost to the scholar. The election of both Fellows and Scholars will be determined with consideration to LSI’s thesis of “Improving the Quality of Life and Saving Lives”.
THE LSI FOUNDATION
LSI from a to-be-determined portion of its profit, will fund the LSI Foundation to provide for free, life saving drugs to the world’s indigent and underserved.
LSI optimizes the development time/success rate trade-off that maximizes valuation and risk-adjusted returns.
By utilizing machine learning/artificial intelligence/quantum computing/advanced mathematical computations to prioritize new targets and accelerate identification of clinical molecules.
Machine learning (AI) at all stages improves: target identification, drug design, biomarkers, patient stratification.
Structure-based drug discovery creates faster and less expensive hit identification and lead optimization.
By increasing critical information content/discussion early, LSI ruthlessly prunes failures to shift attrition to alternative development phases and opportunities to reinvest in further R&D.
The ability to pool and cross-fertilize the genomic information using advanced computational research and bioinformatics accelerates the identification of new drug targets and the design of new clinical studies.
In hand valuable research assets.
Ready access to local clinicians streamlines trials and expands indications.
Leverage national resources and local CROs for best preclinical models, biomarkers and infrastructure.
The use of precision medicine.
Utilizing computational and statistical analysis, together with our LSI Research Partner, we developed the LSI model from the bottom up. Examining our LSI Research Partner’s extensive capabilities in drug candidate discovery and medicines development, we developed a model that accelerates speed to drug development and maximizes financial returns.
LSI SCHOLARS
LSI will support the world’s brightest scholars with scholarships, financial remunerations, stipends, and living expenses, making their education absent of distraction and in turn enabling them to focus on creating medical breakthroughs, improving the quality of life and saving lives.
LSI RESEARCH FELLOWS
The LSI Research Fellows Award provides financial incentive and global recognition to the giants of medicine, honoring their work in the creation of life saving advances in novel medicines development.
THE LSI FOUNDATION
The LSI Foundation, created from a to be determined portion of LSI’s profits, will provide for free, life saving drugs to the world’s indigent and underserved.
LSI’s ACCELERATION AND SPEED OF DRUG DEVELOPMENT
LSI’s acceleration of drug development delivers outsized rates of financial returns. Additionally, LSI’s speed of novel medicines development has a substantive impact on the global health of human kind, saves lives and in turn provides hope for future generations.